for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Momenta Pharmaceuticals, Inc.

MNTA.OQ

Latest Trade

13.38USD

Change

0.06(+0.45%)

Volume

737,640

Today's Range

13.23

 - 

13.61

52 Week Range

9.54

 - 

28.15

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
13.32
Open
13.32
Volume
737,640
3M AVG Volume
11.11
Today's High
13.61
Today's Low
13.23
52 Week High
28.15
52 Week Low
9.54
Shares Out (MIL)
98.71
Market Cap (MIL)
1,314.78
Forward P/E
-5.29
Dividend (Yield %)
--

Next Event

Q3 2019 Momenta Pharmaceuticals Inc Earnings Release

Latest Developments

More

Momenta Pharmaceuticals Reports Q2 Loss Per Share $1.16

Momenta Pharmaceuticals Launches Phase 2/3 Trial Of M281

Momenta Pharmaceuticals Q1 Revenue Estimate $10.1 Million -- Refinitiv Ibes Data

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection). GLATOPA 20 milligrams (mg)/ milliliters (mL) is a generic version of once-daily COPAXONE 20 mg/mL indicated for the treatment of patients with relapsing forms of multiple sclerosis, a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. COPAXONE is available in both a once-daily 20 mg/mL formulation and a three-times-weekly 40 mg/mL formulation. The Company's Enoxaparin Sodium Injection is a generic version of LOVENOX indicated for the prevention and treatment of deep vein thrombosis and to support the treatment of acute coronary syndromes. The Company's programs include M254, M281 (Anti-FcRn candidate) and M230.

Industry

Biotechnology & Drugs

Contact Info

301 Binney St

+1.617.4919700

http://www.momentapharma.com/

Executive Leadership

Craig A. Wheeler

President, Chief Executive Officer, Director

Michelle Robertson

Chief Financial Officer, Treasurer

Jo-Ann Beltramello

Chief Human Resources and Infrastructure Officer

Anthony M. Manning

Chief Scientific Officer

Alejandra V. Carvajal

Chief Legal Officer, General Counsel and Secretary

Key Stats

2.50 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.1K

2017

0.1K

2018

0.1K

2019(E)

0.0K
EPS (USD)

2016

-0.310

2017

-1.200

2018

-2.260

2019(E)

-2.519
Price To Earnings (TTM)
--
Price To Sales (TTM)
19.62
Price To Book (MRQ)
4.20
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-55.45
Return on Equity (TTM)
-49.67

Latest News

Momenta, Amphastar settle generic Lovenox drug patent case

Amphastar Pharmaceuticals Inc on Wednesday said Momenta Pharmaceuticals Inc and Novartis AG's Sandoz unit will pay it $59.9 million to resolve patent and antitrust lawsuits over their dueling generic versions of the blood-thinner Lovenox.

BRIEF-Amphastar Pharmaceuticals Announces Settlement In Litigation With Momenta And Sandoz

* AMPHASTAR PHARMACEUTICALS, INC. ANNOUNCES SETTLEMENT IN LITIGATION WITH MOMENTA AND SANDOZ

Fed Circuit dismisses Momenta Pharmaceuticals patent appeal as moot

A federal appeals court on Thursday dismissed as moot a challenge by Momenta Pharmaceuticals Inc to a Bristol-Myers Squibb Inc patent for treating immune system disorders, saying Momenta had no legally protected interest in the patent.

Amphastar cannot collect $100 mln during Momenta drug patent appeal - judge

A federal judge on Monday ruled that Amphastar Pharmaceuticals Inc must wait to collect a $100 million bond that Momenta Pharmaceuticals Inc and Sandoz Inc posted in a drug patent case it won until after an appellate court hears the dispute.

BRIEF-Momenta Pharmaceuticals Q1 Loss Per Share $0.63

* MOMENTA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Momenta Pharmaceuticals Reports Q4 Earnings Per Share $0.18

* MOMENTA PHARMACEUTICALS REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Momenta Pharmaceuticals Announces FDA Approval And Launch Of Glatopa

* MOMENTA PHARMACEUTICALS ANNOUNCES FDA APPROVAL AND LAUNCH OF GLATOPA® (GLATIRAMER ACETATE INJECTION) 40 MG/ML

BRIEF-Momenta Pharmaceuticals Announces Positive Outcome For Contracted Glatopa

* MOMENTA PHARMACEUTICALS ANNOUNCES POSITIVE OUTCOME FOR CONTRACTED GLATOPA (GLATIRAMER ACETATE INJECTION) FILL/FINISH MANUFACTURER Source text for Eikon: Further company coverage:

BRIEF-Momenta Pharmaceuticals Planning For Glatopa 40 Mg Launch In 2H 2018 However

* MOMENTA PHARMACEUTICALS - CO PLANNING FOR GLATOPA 40 MG LAUNCH IN 2H 2018; HOWEVER, POTENTIAL REMAINS FOR 1H 2018 LAUNCH - SEC FILING Source text:(http://bit.ly/2CTkx5R) Further company coverage:

BRIEF-Momenta Pharmaceuticals Reports Positive Top-Line Phase 1 Data Showing Proof Of Mechanism For M281

* MOMENTA PHARMACEUTICALS REPORTS POSITIVE TOP-LINE PHASE 1 DATA SHOWING PROOF OF MECHANISM FOR M281, AN ANTI-FCRN MONOCLONAL ANTIBODY, IN HEALTHY VOLUNTEERS

Momenta, Mylan plan trial of biosimilar to Regeneron eye drug

Momenta Pharmaceuticals Inc and Mylan NV plan to begin a pivotal clinical trial of a biosimilar to Regeneron Pharmaceuticals Inc's blockbuster eye drug Eylea in the first half of this year, the two companies said on Wednesday.

BRIEF-Momenta And Mylan Announce Development Strategy For Proposed Biosimilar To Eylea

* MOMENTA AND MYLAN ANNOUNCE DEVELOPMENT STRATEGY FOR M710, A PROPOSED BIOSIMILAR TO EYLEA® (AFLIBERCEPT)

BRIEF-Momenta Pharma says Q3 loss per share $0.44

* Momenta Pharmaceuticals reports third quarter 2017 financial results and provides corporate update

BRIEF-Momenta And Mylan report initial results from phase 1 clinical trial for M834

* Momenta And Mylan report initial results from phase 1 clinical trial for M834, a proposed biosimilar of Orencia® (abatacept)

BRIEF-Momenta Pharmaceuticals posts Q2 loss per share $0.50

* Momenta pharmaceuticals reports second quarter 2017 financial results and provides corporate update

BRIEF-Amphastar announces jury verdict in litigation against Momenta Pharmaceuticals and Sandoz Inc

* Amphastar announces jury verdict in patent litigation against Momenta Pharmaceuticals Inc and Sandoz Inc

U.S. jury sides with Amphastar over Momenta in drug patent trial

A federal jury handed Amphastar Pharmaceuticals Inc a big win on Friday after it was accused of infringing on a patent held by Momenta Pharmaceuticals Inc through its production of a generic version of the blood-thinner Lovenox.

U.S. jury sides with Amphastar over Momenta in drug patent trial

A federal jury handed Amphastar Pharmaceuticals Inc a big win on Friday after it was accused of infringing on a patent held by Momenta Pharmaceuticals Inc through its production of a generic version of the blood-thinner Lovenox.

U.S. jury sides with Amphastar over Momenta in drug patent trial

Amphastar Pharmaceuticals Inc on Friday won a trial in a lawsuit claiming that the drugmaker through its production of a generic version of the blood-thinner Lovenox infringed a patent held by Momenta Pharmaceuticals Inc.

Momenta seeks $938 million from Amphastar at drug patent trial's end

A lawyer for Momenta Pharmaceuticals Inc urged a federal jury on Thursday to force Amphastar Pharmaceuticals Inc to pay $938 million for infringing a patent the drugmaker held through its production of a generic version of the blood-thinner Lovenox.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up